Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Investment Income (2023 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Non Operating Investment Income for 2 consecutive years, with -$6.9 million as the latest value for Q1 2024.

  • For Q1 2024, Non Operating Investment Income changed N/A year-over-year to -$6.9 million; the TTM value through Dec 2024 reached -$6.9 million, up 95.39%, while the annual FY2024 figure was -$6.9 million, 95.39% up from the prior year.
  • Non Operating Investment Income hit -$6.9 million in Q1 2024 for Cartesian Therapeutics, up from -$149.6 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at -$6.9 million in Q1 2024 and bottomed at -$149.6 million in Q4 2023.